Drugs / Lederfolin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05253846 | Jan 2022 → Jan 2025 overdue | — | Gruppo Oncologico del Nord-Ovest | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT07213557 Background | Mar 2026 → Sep 2027 expected | gastroesophageal cancer | National Cancer Institute, Naples | Recruiting | No outcome recorded |
| Phase 2 | NCT03874026 Background | Sep 2019 → May 2023 overdue | colorectal cancer | National Cancer Institute, Naples | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00646607 Comparator | Jun 2007 → Apr 2013 | colon carcinoma | Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lederfolin | “mFOLFOX6 (oxaliplatin 85 mg/m2 on day 1 followed by lederfolin 200 mg m2 on day 1, fluorouracil 400 mg m2 on day 1 and 2,400 mg m2 continuous infusion over 46 hours every 2 weeks)” NCT07213557 ↗ |
| Route | Intravenous | “LEDERFOLIN 200 mg/sqm iv over 2 hours, day 1” NCT05253846 ↗ |